In a historic breakthrough for targeted protein degradation, BMS has secured the first FDA approval for a CELMoD therapy with the clearance of Zenbexus (iberdomide), marking the first multiple myeloma approval driven directly by minimal residual disease as a surrogate endpoint.
The True Cost of Focusing on Cost Instead of Cost-Effectiveness
When payors consider only the cost of the medication and not the cost and risk to the patient, doctor, and healthcare system, the irony is
